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sive and targeted transgene expression is crucial. In the
specific setting of heart transplantation, gene transfer to
the donor organ has been accomplished by either direct
myocardial injection1 or intracoronary infusion of a
variety of vectors, such as liposomes and genetically
modified viral particles.2-5 Intramyocardial injection
results in uneven, localized, transgene expression and
incites a marked inflammatory response. Intracoronary
infusion therefore represents a preferable method for
gene delivery in the setting of transplantation.
Adenoviral vectors enter the cells through a 2-step
process: (1) adhesion to a cell membrane receptor6 and
(2) internalization mediated by α
v
β3 and αvβ5 inte-
grins.7,8 This latter step is energy dependent and occurs
at normothermic conditions. Temperature significantly
affects the efficiency of gene transfer in cultured
endothelial and smooth muscle cells and thoracic aorta
in culture.9,10 Continuous hypothermic perfusion of
donor hearts compared with hypothermic immersion
S everal obstacles must be overcome before wide-spread clinical application of gene therapy will be
possible. The development of an effective and clinical-
ly applicable gene-delivery system resulting in exten-
Background: Hypothermic conditions required for donor heart preserva-
tion may reduce gene-transfer efficiency. Experiments were designed to
determine whether a perfusion technique could improve the efficiency
of gene transfer to donor hearts. Methods: An adenoviral vector encod-
ing β-galactosidase (3.5 × 108 plaque-forming units) was infused into
explanted rat hearts under 4 conditions (each n = 6): (1) the virus was
diluted in 350 µL of University of Wisconsin solution and infused as a
high-pressure bolus into the coronary arteries of donor hearts through
the aortic root; (2) the virus was diluted in 5 mL of University of
Wisconsin solution and circulated by means of a peristaltic pump (flow,
0.75 mL/min) through the vasculature of the donor heart for 30 min-
utes; (3) 5 mL of viral solution was circulated as for group 2 for 15 min-
utes; and (4) 5 mL of viral solution was circulated for 5 minutes at a flow
rate of 2.4 mL/min. Transduced hearts were transplanted into the
abdomen of syngeneic rats, and transgene expression was assessed by
means of immunoassay 4 days later. Results: The median β-galactosidase
content was (1) 45.0 ng/mg protein (25th-75th percentile, 33-73 ng/mg),
(2) 640 ng/mg protein (25th-75th percentile, 614-878 ng/mg), (3) 493.8
ng/mg protein (25th-75th percentile, 456-527 ng/mg), and (4) 503.3
ng/mg protein (25th-75th percentile, 475-562 ng/mg; P < .01 for group 2
vs group 1, and P < .05 for groups 3 and 4 vs group 1). Transgene expres-
sion was predominantly in myocytes and favored the subepicardial
region of the right ventricle. Conclusion: Hypothermic perfusion of the
donor heart with an adenoviral vector resulted in efficient transgene
expression compared with that induced by a single bolus injection.
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storage can be used for preservation of donor
organs.11,12 Therefore a modified hypothermic perfu-
sion technique could be applied for gene delivery to
donor hearts.
Experiments were designed to compare the efficiency
of gene transfer and distribution of transgene expression
after ex vivo circulation of an adenoviral vector through
the coronary vasculature of donor hearts. 
Materials and methods
Animals. Inbred male Lewis rats (270-330 g) were used as
donors and recipients for syngeneic transplants. Procedures
and handling of animals were reviewed and approved by the
Institutional Animal Care and Use Committee of the Mayo
Clinic and Foundation in compliance with “Principles of
Laboratory Animal Care” formulated by the National Society
for Medical Research and the “Guide for the Care and Use of
Laboratory Animals” prepared by the Institute of Laboratory
Animal Resources and published by the National Institutes of
Health (National Institutes of Health publication No. 86-23,
revised 1985).
Adenoviral vector. A serotype 5 adenovirus encoding for
nonnuclear targeted Escherichia coli β-galactosidase under
the control of the cytomegalovirus promoter was used in this
study (AdCMVLacZ, provided by James Wilson, Institute for
Gene Therapy, University of Pennsylvania). This vector has
been rendered replication defective by replacing the entire
E1a and most of the E1b regions of the adenoviral genome
with the complementary DNA expression cassette. The
recombinant virus was propagated in transformed human
embryonic kidney carcinoma cells (“293 cells”), which con-
stitutively express E1 proteins; isolated and purified as previ-
ously described13; and stored at –70°C in a buffered solution
of 10% glycerol until use. Viral titers were determined by
means of plaque assay and expressed as plaque-forming units
(PFU) per milliliter.
Donor operation. After anesthesia was obtained (pento-
barbital sodium 70 mg/kg administered intraperitoneally), the
donor rat was intubated and mechanically ventilated (model
683; Harvard Apparatus Inc, South Natick, Mass; tidal vol-
ume: 10 mL/kg, respiratory rate: 60 breaths/min). A median
sternotomy was performed to expose the heart. After injection
of 200 U of aqueous heparin into the inferior vena cava, the
innominate artery was cannulated with a 24-gauge cannula,
and the venae cavae and pulmonary veins were ligated en
bloc with 4-0 silk. The aorta was tied distal to the cannula,
and the heart was arrested with an infusion of cold University
of Wisconsin solution (UWS) into the aortic root through the
indwelling cannula (flow, 0.44 mL/min; duration, 5 minutes).
After harvesting, the heart was stored in the same cardio-
plegic solution at 4°C.
Experimental groups. The efficiency of adenovirus-medi-
ated gene transfer was evaluated in 4 groups (n = 6 in each
group). Rats were randomly assigned to each group. In group
1, 350 µL of UWS containing 3.5 × 108 PFU (titer, 1 × 109
PFU/mL) was infused as a high-pressure bolus (90-110 mm
Hg) over 5 seconds into the coronary artery through the aor-
tic root. The pulmonary artery was clamped during the infu-
sion, and the virus was not flushed out at the end of 60 min-
utes of cold storage before performing the surgical procedure.
In group 2, 5 mL of UWS containing 3.5 × 108 PFU (titer, 7
× 107 PFU/mL) was circulated through the coronary vascula-
ture of the donor organ for 30 minutes by means of a peri-
staltic pump (Rainin, Emeryville, Calif; Fig 1). The viral
solution was infused into the donor organ through the cannu-
la inserted into the aorta and was collected by a 14-gauge
catheter placed into the pulmonary artery. Both catheters
were connected by means of polyvinyl chloride tubing to the
vial containing the viral solution. The flow rate was 0.75
mL/min. As determined in preliminary experiments (n = 3)
by means of a catheter inserted into the left common carotid
artery, this rate generated a pressure of between 40 and 50
mm Hg in the aortic arch. During the perfusion period, the
container with the heart and the vial with the vector were kept
on ice, and the temperatures of both solutions did not exceed
4°C. The entrapment of air was not a problem. To help avoid
this problem, the heart was kept vertical before starting the
microperfusion and during circulation of the viral solution. In
group 3 the effect of reducing the perfusion time and thus the
number of passages of the vector through the donor organ
was evaluated. The same volume of viral solution was circu-
lated into the graft for 15 minutes at the same flow rate as in
group 2. In group 4 the influence of flow rate and, conse-
quently, pressure on transgene expression was assessed. In
this latter group 5 mL of viral solution was circulated for 5
minutes at a flow rate of 2.4 mL/min, generating a pressure
of between 70 and 80 mm Hg in the aortic arch. In control
animals (n = 3 for the single bolus infusion group, low-flow
perfusion groups, and high-flow perfusion group) virus-free
UWS was administered.
Recipient operation. Heterotopic abdominal heart trans-
plantation was performed by using standard microsurgical
techniques.14 Animals were anesthetized by administration of
intraperitoneal pentobarbital (70 mg/kg). In brief, the donor
hearts were transplanted into the recipients by end-to-side
anastomoses of the aorta and the pulmonary artery to the
abdominal aorta and inferior vena cava, respectively, by using
10-0 monofilament sutures. During surgery, the heart was
wrapped in gauze and kept cold by use of topical ice-cold
saline solution. At reperfusion, appearance of each graft was
graded on the basis of the color of the heart and the ventricu-
lar contractility (scale ranging from 1 to 5, with grade 1 rep-
resenting the worst). All rats received analgesia postopera-
tively (butorphanol tartrate 0.3 mg/kg administered
subcutaneously) and recovered with oxygen in a warm envi-
ronment. Function of the graft was checked daily by palpa-
tion of the beating transplanted heart.
Assessment of transgene expression. Four days after
transplantation, the animals were anesthetized with an
intraperitoneal injection of pentobarbital sodium (70 mg/kg),
and the transplanted hearts were removed and flushed with
saline solution. A midventricular section was cut, embedded
in OCT compound (Miles Laboratories, Elkhart, Ind) and
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snap-frozen in a liquid nitrogen–cooled 2-methylbutane bath
for histologic evaluations and X-Gal staining. The remainder
of the ventricles were snap-frozen in liquid nitrogen and then
homogenized (Tekmar tissue homogenizer, Cincinnati, Ohio)
for 3 minutes in ice-cold buffer (100 mmol/L potassium
phosphate [pH 7.8], 0.2% Triton X-100 [Sigma Chemical
Company, St Louis, Mo], and 200 mmol/L phenylmethylsul-
fonyl fluoride). The homogenates were centrifuged at
18,000g for 10 minutes at 4°C. The supernatant was collect-
ed and frozen at –70°C. Transgene expression was quantita-
tively assessed by means of an enzyme-linked immunosor-
bent assay (5´ Prime → 3´; Prime Inc, Boulder, Colo). In
brief, a rabbit polyclonal antibody specific to the E coli β-
galactosidase protein was coated onto polystyrene micro-
wells. When transgene protein is present in tissue extracts
added to the wells, it is captured and bound to the solid phase.
Biotinylated secondary antibody to β-galactosidase then
binds to immobilized primary antibody–β-galactosidase
complex. The biotinylated antibody is quantified colorimetri-
cally by incubation with streptavidin-conjugated alkaline
phosphatase and color development substrate. Spectro-
photometric analysis was performed on an automated ana-
lyzer (SPECTRAmax 340; Molecular Devices Corporation,
Sunnyvale, Calif). By the same technique, transgene expres-
sion was also determined in recipient native organs (thigh
skeletal muscle, testis, liver, lung, and heart) to evaluate the
potential release into the systemic circulation and dissemina-
tion of the viral vector after restoration of the blood flow to
the transplanted heart.
Additional aliquots of supernatant were used to assess total
protein concentration by using bicinchoninic acid protein
assay reagent (Pierce, Rockford, Ill).
Histology. The cellular distribution of transgene expres-
sion was evaluated by using X-Gal staining. Three 5-µm
thick cryostat sections were cut at 25-µm intervals from the
midventricular section. Sections were fixed in 1.25% glu-
taraldehyde for 15 minutes at 4°C and then rinsed twice with
phosphate-buffered saline solution (Gibco BRL, Gaithersburg,
Md). Sections were stained in a solution of 500 µg/mL 5-
bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal;
Boehringer Mannheim Corp, Indianapolis, Ind) for 4 hours at
37°C and then were rinsed in phosphate-buffered saline solu-
tion and counterstained with eosin. Blue-stained cells indi-
cated the presence of β-galactosidase expression.
Adjacent slides were cut and stained with hematoxylin and
eosin for routine histopathologic examination. Inflammation
and ischemic damage were graded by an experienced cardiac
pathologist blinded to the origin of the slides. Inflammation
was scored on a scale comparable with the working formula-
tion for cardiac rejection,15 whereas the following scale was
used for ischemic damage: 0, no ischemic damage; 1, less
than 5% of the area of the section; 2, between 5% and 20%
of the area; 3, between 20% and 40% of the area; and 4, more
than 40% of the area.
To quantify transduction efficiency, 3 cross-sections of the
heart from each rat were studied. Each region (subepicardi-
um, midmyocardium, and subendocardium) was divided into
8 quadrants. For each quadrant, positive-staining cells and
Fig 1. Illustration of the gene delivery system used in the current study. The solution containing the adenoviral
vector was perfused from a vial through the vasculature of the donor heart and back to the vial by means of a peri-
staltic pump (left). The container with the heart immersed in UWS and the vial with the viral solution were kept
on ice during the circulation time. The inset depicts the inflow and outflow catheters placed in the aorta and pul-
monary artery, respectively.
496 Pellegrini et al The Journal of Thoracic and
Cardiovascular Surgery
March 2000
total cells were counted in one high-power (×400) field in the
subepicardial region, the midwall, and the subendocardial
region. Transduction efficiency was calculated as the number
of positively stained cells divided by the number of total cells
in the quadrant considered. A total of 72 quadrants per heart
were analyzed.
Statistical analysis. Results are expressed as medians and
ranges when data did not follow a Gaussian distribution and
variances were unequal. A nonparametric test (Kruskal-
Wallis) of analysis of variance, followed by the Dunn post
hoc test for paired comparisons, was performed to evaluate
differences in these cases. Results are expressed as means ±
standard deviation when data followed a Gaussian distribu-
tion. In these cases statistical analysis was performed by
using an analysis of variance test, followed by the Bonferroni
post hoc test for paired comparisons. Correlation was evalu-
ated by the nonparametric Spearman test by using pooled
data from all the groups. A P value of <.05 was considered
significant.
Results
Operative data. All perfused hearts resumed beat-
ing within 2 to 7 minutes after reperfusion, showing
no differences between the groups. Hearts from the
single bolus infusion group resumed beating in less
than 1 minute after reperfusion. The appearance score
was significantly lower in group 4 compared with the
other groups despite a shorter total ischemic time
(Table I). Total ischemic time was significantly longer
in groups 2 and 3 compared with the other groups
(Table I). There was no operative mortality. All trans-
planted hearts were beating at harvest (postoperative
day 4).
Transgene expression. An 11- to 14-fold increase in
transgene expression was observed in the transplanted
hearts in which the virus was perfused compared with
those undergoing the high-pressure bolus injection. The
median β-galactosidase content, as determined by
using an enzyme-linked immunosorbent assay, was
45.0 ng/mg protein (25th-75th percentile, 33-73
ng/mg) in group 1, 640 ng/mg protein (25th-75th per-
centile, 614-878 ng/mg) in group 2, 493.8 ng/mg pro-
tein (25th-75th percentile, 456-527 ng/mg) in group 3,
and 503.3 ng/mg protein (25th-75th percentile, 475-
562 ng/mg) in group 4 (P < .01 for group 2 vs group 1
and P < .05 for groups 3 and 4 vs group 1; Fig 2). No
differences were observed among the groups in which
the vector was perfused into the donor organ.
There was no significant correlation between the level
of transgene expression and either the total ischemic
time (corresponding to the vector dwelling time; r =
0.3322, P = .1127) or the warm ischemic time (corre-
sponding to the implantation time of the donor heart; r
= –0.3456, P = .1601).
Transgene expression was not detected either in the
transplanted hearts of control animals or in the native
organs of any of the transduced animals.
Distribution of transgene expression and histolog-
ic characteristics. Myocytes, endothelial cells, and
interstitial fibroblasts stained positively for β-galactosi-
dase in the transduced hearts (Fig 3). Myocytes were
the most frequently transduced cells, whereas only rare
endothelial cells expressed the transgene. In 75% of the
hearts from groups 2, 3, and 4, transgene expression
was accentuated in the right ventricle compared with
the left ventricle. Efficiency of transduction was signif-
icantly higher in the subepicardial region of groups 2
and 3 compared with group 1. No statistically signifi-
cant differences were observed in the efficiency of gene
transfer in the midwall and the subendocardial regions
of all groups (Table II).
Mild lymphocytic unifocal inflammatory cell infil-
trates were observed in 3 (12.5%) of 24 specimens (1
each for groups 1, 3, and 4).
Ischemia was characterized by patchy foci of coagu-
lative necrosis surrounded by a zone of interstitial
edema. Although groups 2 and 3 had a significantly
Table I. Operative data
Appearance score Total ischemic time (min) Ischemic damage score
Group 1 (high-pressure bolus) 3.33 ± 0.82 119.7 ± 3.2 1.0 ± 0.89
Group 2 (low-pressure pump, 30 min) 3.17 ± 1.33 132.2 ± 6.3* 1.33 ± 1.03
Group 3 (low-pressure pump, 15 min) 3.17 ± 1.33 126.2 ± 9.1† 1.33 ± 1.03
Group 4 (high-pressure pump, 5 min) 1.33 ± 0.52‡ 109.7 ± 6.9 1.67 ± 1.21
Values are shown as means ± SD (n = 6 for each group). Statistical analysis was performed by using the analysis of variance test, followed by the Bonferroni post
hoc test for paired comparison. Appearance score scale ranges from 1 to 5, with grade 1 representing the worst score. For ischemic damage score, see the “Methods”
section. Total ischemic time is defined as implantation time plus time needed for preparation of microperfusion, circulation of viral solution, and recipient prepara-
tion. The implantation time was always less than 45 minutes.
*Denotes statistically significant difference versus groups 1 and 4 (P < .05).
†Denotes statistically significant difference versus group 4 (P < .05).
‡Denotes statistically significant difference versus groups 1, 2, and 3 (P < .05).
The Journal of Thoracic and
Cardiovascular Surgery
Volume 119, Number 3
Pellegrini et al 497
longer total ischemic time compared with the other
groups, the extent of ischemic damage was similar
among the groups (Table I).
Discussion
The current study demonstrates highly efficient ade-
novirus-mediated gene transfer to donor hearts during
hypothermic storage of the organ. The technique of
perfusing the vector provided an 11- to 14-fold increase
in transgene expression compared with the high-pres-
sure bolus injection. This method allowed a 30-fold
reduction in the viral dose compared with that found in
other reports,16,17 without affecting the level of trans-
gene expression.
Gene transfer to the transplanted heart has been
accomplished either by direct injection into the
myocardium or by different techniques using intra-
coronary infusion of vectors, such as cationic and
hemagglutining virus of Japan18 liposomes or replica-
tion-defective adenovirus. Gene transfer after direct
intramyocardial injection is very efficient; however,
transgene expression is localized in an area of 1 to 2
mm along the needle track. Wang and colleagues1 did
not observe inflammation on the seventh postoperative
day, but it is known from other in vivo studies19-21 that
this delivery method is associated with an intense
inflammatory response that, along with the spatial lim-
itation of transgene expression, considerably limits the
application of this technique.
Two methods of intracoronary infusion have been used
to date. The first method consists of administration of the
vector through the coronary vasculature as a rapid, high-
pressure, bolus injection.22,23 This method results in even
distribution of transgene expression throughout the
donor organ as compared with the direct injection; how-
ever, transduction efficiency is low, with fewer than 5%
of cells transduced.3 The second method uses a slow
low-pressure infusion into the coronary vasculature. In
the study from Shiraishi and colleagues,24 this method
did not result in more efficient gene transfer over bolus
injection, despite the use of a large amount of virus (5 ×
1010 PFU/g of tissue). Indeed, the content of recombi-
nant β-galactosidase (98.3 ± 18.9 ng/mg protein) was
similar to the level of transgene expression previously
found after rapid bolus administration. Other authors,
however, have achieved more efficient gene transfer with
slow infusion. With an infusion time of 20 minutes,
Brauner and colleagues16 increased the adenoviral vec-
tor uptake into the donor organ to 80% with the slow-
infusion technique (compared with 10% with bolus
Fig 2. Administration of an adenoviral vector with a peristaltic pump increases transgene expression by 11- to
14-fold. Asterisks denote statistically significant differences versus the bolus injection group, as determined by
using the nonparametric analysis of variance test (Kruskal-Wallis; P < .01 for low-pressure 30-minute pump and
P < .05 for low-pressure 15-minute and high-pressure 5-minute pumps). No difference in transgene expression
was observed among the groups in which the vector was pumped through the donor hearts. Boxes represents 25th
median and 75th percentiles, whereas bars denote the range of β-galactosidase content (n = 6 for each group).
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injection), and the percentage of transduced cells rose to
25% and 40% in the subendocardial and subepicardial
regions, respectively.17
In the current study the vector was initially perfused
through the vasculature of the donor heart for 30 min-
utes. This procedure resulted in highly efficient gene
transfer when compared with bolus administration.
Concerns about a prolongation of donor organ
ischemia, however, led us to reduce the perfusion time.
A 50% reduction to 15 minutes did not significantly
affect the level of transgene expression. Although the
need for hypothermic perfusion may complicate the
system of gene delivery in practice, this will be neces-
sary because a single bolus results in inefficient gene
transfer. More important, in the present experiments a
substantially smaller dose of adenoviral vector was
Fig 3. Light photomicrographs of sections of transplanted hearts from each experimental group (left panel, ×1;
right panel, ×50). The blue-stained cells indicate β-galactosidase expression. All cell types (myocytes, endothe-
lial cells, and interstitial fibroblasts) stained positively for the marker gene. Myocytes were the most frequently
transduced cells, whereas only a few endothelial cells expressed the transgene protein. Staining is more accentu-
ated in the subepicardial region and in the right ventricular wall.
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used. Brauner and colleagues16 used a dose of 1 × 1010
PFU/g of tissue, which is about 30 times greater than
the amount used in the current study (3.5 × 108 PFU/g
tissue). Use of lower doses of adenoviral vectors may
avoid some of the toxicity associated with this mode of
gene transfer. Indeed, no significant inflammatory
response was observed in the transduced hearts, which
may have been due to the low viral dose used or the
time point studied. In a nontransplant setting efficient
gene transfer to the heart has been reported by means
of intracoronary perfusion.25 In addition, this group has
shown that the virus exposure time could be decreased
by enhancement of microvascular permeability.26
Although these articles showed 96% efficiency, it
should be noted that the gene transfer was not accom-
plished under hypothermic conditions. Our results are
therefore more applicable to the transplantation setting.
It is of interest that transgene expression was not
evenly distributed in the transplanted hearts. The pat-
tern correlated fairly closely with the observations after
slow infusion of the vectors17 and was represented by
efficient transgene expression in the perivascular areas
and in the subepicardial region, which progressively
decreased, moving toward the subendocardial region of
the organ. Moreover, transgene expression appeared
somewhat accentuated in the right ventricle compared
with the left ventricle. (Atria were excluded from stain-
ing sections of the transplanted hearts.) The reason for
this pattern of transgene expression is not clear. This is
in contrast to the findings observed after either rapid or
slow infusion of the vector. Indeed, no differences
could be detected in transgene expression in different
regions of the heart after rapid infusion of the vec-
tors,23,27 whereas a significantly lower level of the
transgene product was observed in the right ventricle
after slow infusion.17 The predominant transduction of
the right ventricle obtained with the current method
may represent an important approach by gene therapy
to pathologic processes that affect this chamber.
Increasing the perfusion flow rate did not extend trans-
gene expression to the midwall and subendocardial
regions. Despite the use of a higher perfusion pressure,
no alteration in the distribution of transgene expression
in the graft could be observed. The appearance of the
heart after reperfusion, however, did appear adversely
affected by the high perfusion rate. No difference in the
extent of ischemic damage could be detected in the
experimental groups by means of routine histologic
analysis.
A limitation of this study is that the transplanted
heart was nonworking and unloaded. Thus no function-
al assessments were performed in these grafts. It is
therefore important to carry out additional experiments
in transplanted working hearts to establish the actual
effect of this technique on ventricular function. In addi-
tion, these studies used a reporter gene, and future stud-
ies with physiologically relevant genes will be per-
formed by using this method.
In summary, the current study demonstrates that high
levels of transgene expression are achievable in trans-
planted hearts with the use of modest amounts of ade-
noviral vector in hypothermic conditions by perfusion
of the virus through the coronary vasculature.
We thank Sharon Guy and Sandra Severson for their skill-
ful technical assistance.
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